Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The standard treatment for patients with Non-Small Cell Lung Cancer (NSCLC) and clinically
negative lymph nodes remains surgery per current guidelines. Five year survival for patients
with stage I non-small cell lung cancer is generally greater than 50% after surgery. Many of
these patients have heart and lung issues or other diseases which keep them from undergoing
curative surgery. Studies have shown that majority of these patients die from their cancer
and not from their other diseases. This is the reason for treating early stage lung cancer
patients with definitive therapy, when they cannot have surgery. This study will enroll
twelve subjects to evaluate the side effects of this treatment, and decide if it is a good
option for the patients that cannot have surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
State University of New York - Upstate Medical University